Novo Nordisk's Wegovy pill achieved 18,410 U.S. prescriptions in the first full week following its January 5 launch, according to IQVIA data shared by an analyst.
Strong Start Outpaces Competitors
The pill reached 3,071 prescriptions in the initial four days. "We note this is tracking ahead of other GLP-1 launches," Guggenheim analysts stated in a research note.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Investor Focus on Market Leadership
Investors monitor prescription trends closely as Novo seeks to leverage its first-mover advantage against Eli Lilly in the booming weight-loss sector. Under new CEO Mike Doustdar, who assumed leadership last year, Novo aims to attract new users with this blockbuster treatment's pill form amid prior sales slowdowns.
Novo's shares climbed 25% in January, rising 2.5% on Friday to a high not seen since late July.
Future of Oral Obesity Drugs
- The U.S. FDA anticipates a decision on Eli Lilly's experimental pill by April.
- Oral options provide needle-free convenience and flexibility for patients.
- Injectables remain dominant, but pills expand access to obesity treatments.